A groundbreaking study in the New England Journal of Medicine reveals improved survival outcomes in adults with B-cell acute lymphoblastic leukemia through blinatumomab immunotherapy.
- Blinatumomab immunotherapy in B-cell precursor acute lymphoblastic leukemia patients in remission with negative measurable residual disease (MRD) after initial chemotherapy led to a significant improvement in survival.
- The 3-year follow-up showed that 85% of patients who received blinatumomab in addition to standard consolidation chemotherapy were alive, compared to 68% of those who received chemotherapy only.
- Blinatumomab is a BiTE immuno-oncology therapy that targets CD19 surface antigens on B cells, improving the body’s immune system’s ability to detect and target malignant cells.
- The US FDA approved the use of blinatumomab in CD19-positive B-cell precursor acute lymphoblastic leukemia patients based on the positive E1910 trial results.
- Patients who received blinatumomab experienced manageable toxicities, with improvements in overall and relapse-free survival especially notable in patients aged 30 to 55.
Oncology, Hematology, Clinical Trial